Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, briefly comments on the use of PET-guided treatment in Hodgkin lymphoma (HL) and further discusses factors which may influence whether this becomes the new standard of care (SOC) in this disease. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.